# Phase I Study of OPC-61815

> **NCT03510663** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** OPC-61815 16mg
- **DRUG:** OPC-61815 32mg
- **DRUG:** Moxifloxacin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03510663
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2018-07-05
- **Final completion:** 2018-07-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03510663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03510663, "Phase I Study of OPC-61815". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03510663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*